Furthermore, LAT1 is overexpressed in numerous cancer types, e.g., brain (Nawashiro et al., 2006), breast (Kurozumi et al., 2022), gastric (Ichinoe et al., 2011), lung (Kaira et al., 2008), pancreatic (Kaira et al., 2012), prostate (Sakata et al., 2009), renal cell (Betsunoh et al., 2013) and urologic cancer (Nakanishi et al., 2007) (also see (Wang and Holst, 2015) and (Häfliger and Charles, 2019) for LAT1 expression in other tumors), and is used as a pathological factor for an unfavorable prognosis in patients. Here, SLC7A5 is linked to cancer.